Slow-release oral morphine: Difference between revisions
From IDWiki
(Created page with "== Dosing == === BC OUD Guidelines === * Increase doses q48h * When transitioning from methadone, the eventual dose will usually be 6- to 8-times higher, but generally sho...") |
No edit summary |
||
Line 1: | Line 1: | ||
== |
== Background == |
||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
⚫ | |||
* Morphine sulphate sustained release capsules (Kadian) |
|||
⚫ | |||
** Beads contain both immediate release and slow release morphine |
|||
** IR released by stomach acid and SR released in bowels at higher pH |
|||
** Capsules themselves may pass in the stool |
|||
* Full opioid agonist |
|||
* Approved for chronic pain, but used off-label for [[opioid use disorder]] |
|||
* Appears likely to be equivalent to [[methadone]], but higher patient satisfaction |
|||
* Peak plasma level 8.5 to 10 hours |
|||
* Elimination half life 11 13 hours |
|||
==Dosing== |
|||
* For daily dispensed, often opened and sprinkled on apple sauce or yoghurt, or water |
|||
* Capsule sizes include 10, 20, 50, and 100 mg |
|||
* Specify on the prescription if it is being used for OUD or chronic pain |
|||
⚫ | |||
*Eligible in age >19 and switching from methadone or actively using opioids |
|||
⚫ | |||
⚫ | |||
⚫ | |||
**Increase doses q48h based on withdrawal symptoms |
|||
⚫ | |||
⚫ | |||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!Number missed!!Action |
||
|- |
|- |
||
| |
|1||no change |
||
|- |
|- |
||
| |
|2||40% reduction |
||
|- |
|- |
||
| |
|3||60% reduction |
||
|- |
|- |
||
|4||80% reduction |
|||
| 4 || 40 mg or starting dose |
|||
|- |
|- |
||
| |
|5||re-initiate |
||
|} |
|} |
||
=== |
===St. Michael's Protocol=== |
||
{| class="wikitable" |
{| class="wikitable" |
||
! |
!Day!!Slow-release morphine!!Instant-release morphine |
||
|- |
|- |
||
| |
|1||200-300 mg||30-50 mg po q2h while awake + 30-50 mg po q3h prn |
||
|- |
|- |
||
| |
|2||SR dose from Day 1 + 50% of IR dose from Day 3||30-50 mg po q2h while awake + 30-50 mg po q3h prn |
||
|- |
|- |
||
| |
|3||SR dose from Day 2||30-50 mg po q3h prn |
||
|- |
|- |
||
| |
|4||SR dose from Day 3 + 50% of IR dose from Day 3||30-50 mg po q3h prn |
||
|- |
|- |
||
| |
|5||SR dose from Day 4||30-50 mg po q3h prn |
||
|- |
|- |
||
| |
|6||SR dose from Day 5 + 50% of IR dose from Day 5||30-50 mg po q3h prn |
||
|} |
|} |
||
=== Off-Guideline === |
|||
* For induction from methadone or non-methadone opioids with high opioid tolerance |
|||
* Start at 200 to 300 mg, then increase by 100 to 150 q48h |
|||
* Missed days |
|||
** 1: full |
|||
** 2: 50% reduction |
|||
** 3: 75% reduction or resume at initiation dose |
|||
** 4: resume at initiation dose |
|||
=== Carries === |
|||
* Per guidelines, doses should be indefinitely witness ingestion |
|||
* However, may be reasonable to do same for [[methadone]] |
|||
** No carrier x 8 weeks, then one carry per week every month with weekly urine drug screens |
|||
=== Switch to Methadone === |
|||
* Must stop SROM and start [[methadone]] titration from 30 mg |
|||
=== Switch to M-Eslon === |
|||
* Split SROM dose for BID M-Eslon |
|||
* Dosages include 10, 15, 30, 60, 100, and 200 mg |
|||
== Safety == |
|||
* Adverse effects include GI cramping, abdominal pain, headache, hyperhidrosis, constipation, frequent urination, nausea/vomiting, and insomnia |
|||
* Risk of respiratory depression and other forms of [[opioid toxicity]] |
|||
* Safe in pregnancy |
|||
** Small RCT suggests no difference from [[methadone]] in neonatal outcomes but possibly lower unprescribed drug use in SROM |
|||
=== Contraindications === |
|||
* Hypersensitivity to morphine |
|||
* Respiratory |
|||
** Significant respiratory depression |
|||
** Acute or severe bronchial asthma |
|||
** Severe respiratory compromise or obstructive disease |
|||
* Gastrointestinal |
|||
** Known or suspected paralytic ileus |
|||
** Short gut syndrome of transit time abnormalities |
|||
* Alcohol use |
|||
* MAOI use within 14 days |
|||
[[Category:Medications]] |
[[Category:Medications]] |
Revision as of 01:07, 11 February 2021
Background
- Morphine sulphate sustained release capsules (Kadian)
- Beads contain both immediate release and slow release morphine
- IR released by stomach acid and SR released in bowels at higher pH
- Capsules themselves may pass in the stool
- Full opioid agonist
- Approved for chronic pain, but used off-label for opioid use disorder
- Appears likely to be equivalent to methadone, but higher patient satisfaction
- Peak plasma level 8.5 to 10 hours
- Elimination half life 11 13 hours
Dosing
- For daily dispensed, often opened and sprinkled on apple sauce or yoghurt, or water
- Capsule sizes include 10, 20, 50, and 100 mg
- Specify on the prescription if it is being used for OUD or chronic pain
BC OUD Guidelines
- Eligible in age >19 and switching from methadone or actively using opioids
- When transitioning from methadone, the eventual dose will usually be 8 times higher, but generally should start with a 4-times higher dose to be safe
- Increase by 30 to 60 mg daily q48h
- For other opioids, start with dose of 30 to 60 mg
- Increase doses q48h based on withdrawal symptoms
- Average stable doses are 60 to 1200 mg daily
Missed Doses
Number missed | Action |
---|---|
1 | no change |
2 | 40% reduction |
3 | 60% reduction |
4 | 80% reduction |
5 | re-initiate |
St. Michael's Protocol
Day | Slow-release morphine | Instant-release morphine |
---|---|---|
1 | 200-300 mg | 30-50 mg po q2h while awake + 30-50 mg po q3h prn |
2 | SR dose from Day 1 + 50% of IR dose from Day 3 | 30-50 mg po q2h while awake + 30-50 mg po q3h prn |
3 | SR dose from Day 2 | 30-50 mg po q3h prn |
4 | SR dose from Day 3 + 50% of IR dose from Day 3 | 30-50 mg po q3h prn |
5 | SR dose from Day 4 | 30-50 mg po q3h prn |
6 | SR dose from Day 5 + 50% of IR dose from Day 5 | 30-50 mg po q3h prn |
Off-Guideline
- For induction from methadone or non-methadone opioids with high opioid tolerance
- Start at 200 to 300 mg, then increase by 100 to 150 q48h
- Missed days
- 1: full
- 2: 50% reduction
- 3: 75% reduction or resume at initiation dose
- 4: resume at initiation dose
Carries
- Per guidelines, doses should be indefinitely witness ingestion
- However, may be reasonable to do same for methadone
- No carrier x 8 weeks, then one carry per week every month with weekly urine drug screens
Switch to Methadone
- Must stop SROM and start methadone titration from 30 mg
Switch to M-Eslon
- Split SROM dose for BID M-Eslon
- Dosages include 10, 15, 30, 60, 100, and 200 mg
Safety
- Adverse effects include GI cramping, abdominal pain, headache, hyperhidrosis, constipation, frequent urination, nausea/vomiting, and insomnia
- Risk of respiratory depression and other forms of opioid toxicity
- Safe in pregnancy
- Small RCT suggests no difference from methadone in neonatal outcomes but possibly lower unprescribed drug use in SROM
Contraindications
- Hypersensitivity to morphine
- Respiratory
- Significant respiratory depression
- Acute or severe bronchial asthma
- Severe respiratory compromise or obstructive disease
- Gastrointestinal
- Known or suspected paralytic ileus
- Short gut syndrome of transit time abnormalities
- Alcohol use
- MAOI use within 14 days